REFERENCES
- Sanders J, Monogue M, Tomasz Z. Jodlowski, Cutrell J. Pharmacologic
Treatments for Coronavirus Disease 2019 (COVID-19) A Review JAMA.
doi:10.1001/jama.2020.6019
- Fedson DS, Jacobson JR, Rordam OM, Opal SM. 2015. Treating the host
response to Ebola virus disease with generic statins and angiotensin
receptor blockers. mBio 6:e00716-15.
https://doi.org/10.1128/mBio.00716-15.
- Fedson D.S. 2016. Treating the host response to emerging virus
diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.
Ann Transl Med 4:421. https://doi.org/10.21037/atm.2016.11.03
- Fedson D.S.. Observational studies help us understand how to treat
pandemic influenza and other emerging virus diseases J Emerg Crit Care
Med 2017;1:10
- Fedson DS, Opal SM, Rordam OM. 2020. Hiding in plain sight: an
approach to treating patients with severe COVID-19 infection. mBio
11:e00398-20. https://doi.org/ 10.1128/mBio.00398-20.
- Yan Y, Liu Q, Li N, Du JC, Li X, Li C, Jin NY, Jiang CY. Angiotensin
II receptor blocker as a novel therapy in acute lung injury induced by
avian influenza A H5N1 virus infection in mouse. Sci China Life Sci,
2015, 58: 208–211, doi: 10.1007/s11427-015-4814-7.
- Martin and Bowden.
https://www.mja.com.au/journal/2020/drug-repurposing-era-covid-market-failure-needing-leadership-and-government-investment
Print June 6, 2020. Online, accessed May 30, 2020.
- Martin JH, Clark J, Head R. Buying time: Drug repurposing to treat the
host in COVID-19H Pharmacol Res Perspect. 2020;00:e00620.
https://doi.org/10.1002/prp2.620
- Pirofski L, and Casadevalli A. The Damage–Response Framework as a
Tool for the Physician-Scientist to Understand the Pathogenesis of
Infectious Diseases JID 2018:218 (Suppl 1):
S7
- Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress,
challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41‐58.
doi:10.1038/nrd.2018.168
- Kreutz R, Algharably E, Azizi M,
et al. Hypertension, the renin–angiotensin system, and the risk of
lower respiratory tract infections and lung injury: implications for
COVID-19 European Society of Hypertension COVID-19 Task Force Review
of Evidence Cardiovascular Research (2020) 0, 1–12 REVIEW
doi:10.1093/cvr/cvaa097
- Verdecchiaa P, Cavallinia C,
Spanevellob A, et al The pivotal link between ACE2 deficiency and
SARS-CoV-2 infection. European Journal of Internal Medicine,
https://doi.org/10.1016/j.ejim.2020.04.037.
- Danser J, Epstein M, Batlle D.
Renin-Angiotensin System Blockers and the COVID-19 Pandemic. At
Present There Is No Evidence to Abandon Renin-Angiotensin System
Blockers. Hypertension. 2020;75:00-00. DOI:
10.1161/HYPERTENSIONAHA.120.15082.
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M,
Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting
enzyme 2 is a functional receptor for the SARS coronavirus. Nature.
2003;426:450–454. doi:10.1038/nature02145.
- Brandon M H, Jens V, Giuseppe L. Response to the emerging novel
coronavirus outbreak. BMJ 2020;368:m406.
- Kuba K, Imai Y, Rao S, Gao H et al. A crucial role of angiotensin
converting enzyme 2 (ACE2) in SARS-coronavirus-induced lung injury.
Nat Med,2005, 11: 875–879.
- Imai Y, Kuba K and Penninger J. The discovery of
angiotensin-converting enzyme 2 and its role in acute lung injury in
mice Exp Physiol 2008 93.5 pp 543–548 543.
- Veerappan A, Reid, A, Estephan R, O’Connor N, Thadani-Mulero M,
Salazar-Rodriguez M, Levi R, and Silver R. Mast cell renin and a local
renin–angiotensin system in the airway: Role in bronchoconstriction
PNAS; January 29, 2008; vol.105(4):1315–1320.
- Jonas S, Erjefa J. Mast cells in human airways: the culprit? Eur
Respir Rev 2014; 23: 299–307. DOI: 10.1183/09059180.00005014.
- Becker BF. All because of the mast cell: blocking the angiotensin
receptor-1 should be better than inhibiting ACE (theoretically)
Cardiovascular Research (2011) 92, 7–9; doi:10.1093/cvr/cvr214
- Bernstein K, Khan Z, Giani J, Cao D-Y, Bernstein E, Shen X.
Angiotensin-converting enzyme in innate and adaptive immunity Nat Rev
Nephrol. 2018 May ; 14(5): 325–336. doi:10.1038/nrneph.2018.15
- Coperchinia F, Chiovatoa L, Crocea, L, et al. The cytokine storm in
COVID-19: An overview of the involvement of the
chemokine/chemokine-receptor system. Cytokine and Growth Factor
Reviews,
https://doi.org/10.1016/j.cytogfr.2020.05.003
- McGonagle D, O’Donnell J.S., Sharif K, Emery P, Bridgewood C. Immune
mechanisms of pulmonary intravascular coagulopathy in COVID-19
pneumonia.
www.thelancet.com/rheumatology
Published online May 7, 2020
https://doi.org/10.1016/S2665-9913(20)30121-1.
- Teuwen L-A, Geldhof V, Pasut A and Carmeliet P. COVID-19: the
vasculature unleashed Nature Reviews/Immunology 2020https://doi.org/10.1038/s41577-020-0343-0.
- Wei Cao and Taisheng Li Research highlight COVID-19: towards
understanding of pathogenesis Cell Research (2020) 30:367–369;
https://doi.org/10.1038/s41422-020-0327-4
- Hemnes A, Rathinasabapathy A, Austin E, et al. A potential therapeutic
role for Angiotensin Converting Enzyme 2 in human pulmonary arterial
hypertension Eur Respir J. 2018 June ; 51(6).
doi:10.1183/13993003.02638-2017.
- Dyer
S, Frewin
D, Head R. The Influence of Chronic Captopril Treatment and Its
Withdrawal on Endothelium-Dependent Relaxation. Blood Press.1992
Dec;1(4):247-53. doi: 10.3109/08037059209077670
- Freund-Michel V, Cardoso Dos Santos M, Guignabert C, et al. Role of
Nerve Growth Factor in Development and Persistence of Experimental
Pulmonary Hypertension. Am J Respir Crit Care Med Vol 192, Iss 3, pp
342–355, Aug 1, 2015.
- S.
Jeffreson R.
Rush C.
Zettler D.
B.
Frewin R.
J. Head THE INFLUENCE OF THE RENIN ANGIOTENSIN SYSTEM ON ABNORMAL
EXPRESSION OF NERVE GROWTH FACTOR IN THE SPONTANEOUSLY HYPERTENSIVE
RAT
Volume22, Issue6‐7July
1995 Pages 478-480
https://doi.org/10.1111/j.1440-1681.1995.tb02050.x
- Gonzalez‑Jaramillo N, Low N, Franco O. The double burden of disease
of COVID‑19 in cardiovascular patients: overlapping conditions could
lead to overlapping treatments. European Journal of Epidemiology
(2020) 35:335–337 https://doi.org/10.1007/s10654-020-
- Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation
hot spots include a novel RNA-dependent-RNA polymerase variant. J
Transl Med. 2020;18(1):179. Published 2020 Apr 22.
doi:10.1186/s12967-020-02344-6
- Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II,
and RAS inhibitors—lessons from available evidence and insights into
COVID-19. Hypertens Res (2020).
https://doi.org/10.1038/s41440-020-0455-8.
- South A, Diz D, and Chappell M. PERSPECTIVES Integrative
Cardiovascular Physiology and Pathophysiology COVID-19, ACE2, and the
cardiovascular consequences Am J Physiol Heart Circ Physiol 318:
H1084–H1090, 2020. doi:10.1152/ajpheart.00217.2020.
- Wu
K,
Lang
Chen L, G, et al. A Virus-Binding Hot Spot on Human
Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two
Different Coronaviruses.
J Virol.
2011 Jun; 85(11): 5331–5337.
doi: 10.1128/JVI.02274-10
- Shahid Z, Kalayanamitra R, McClafferty B et al. COVID-19 and Older
Adults: What We Know J Am Geriatr Soc 68:926-929, 2020.
- Vajapey R, Rini D, Walston J and Abadir P. The impact of age-related
dysregulation of the angiotensin system on mitochondrial redox
balance. Frontiers in Physiology | Mitochondrial Research
November 2014; Volume5; Article439, page 2.
- Wilson B, Nautiyal M, Tan Ya M. Evidence for a mitochondrial
angiotensin-(1–7) system in the kidney. Am J Physiol Renal Physiol
310: F637–F645, 2016. First published December 23, 2015;
doi:10.1152/ajprenal.00479.2015
- Wang J, Chen S, Bihl J et al. Exosome-Mediated Transfer of ACE2
(Angiotensin-Converting Enzyme 2) from Endothelial Progenitor Cells
Promotes Survival and Function of Endothelial Cell. Oxidative Medicine
and Cellular Longevity Volume 2020, Article ID 4213541
https://doi.org/10.1155/2020/4213541
- Lai C, Jou M, Huang S et al.. Proteomic analysis of up-regulated
proteins in human promonocyte cells expressing severe acute
respiratory syndrome coronavirus 3C-like protease Proteomics 2007, 7,
1446–1460
- de Cavanagh E, Piotrkowski B, Basso N et al. Enalapril and losartan
attenuate mitochondrial dysfunction in aged rats The FASEB Journal
express article 10.1096/fj.02-0063fje. Published online April 22, 2003
- Vaduganathan M, Vardeny O, Michel T, McMurray J, Pfeffer M, Solomon S.
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with
Covid-19. N Engl J Med 382;17; April 23, 2020
- Peng Zhang; Lihua Zhu; Jingjing Cai; et al. Association of Inpatient
Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II
Receptor Blockers with Mortality Among Patients With Hypertension
Hospitalized With COVID-19 DOI: 10.1161/CIRCRESAHA.120.317134.
- Mehra M, Desai S, Kuy, S. Timothy D. Henry and Amit N. Patel.
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N
Engl J Med 2020; 382:e102. DOI: 10.1056/NEJMoa2007621
- Meng J, Xiao G, Zhang J et al. (2020) Renin-angiotensin system
inhibitors improve the clinical outcomes of COVID-19 patients with
hypertension, Emerging Microbes & Infections, 9:1, 757-760, DOI:
10.1080/22221751.2020.1746200
- Bean D, Kraljevic Z, Searle T. ACE-inhibitors and Angiotensin-2
Receptor Blockers are not associated with severe SARS- COVID19
infection in a multi-site UK acute Hospital Trust
medRxiv 2020.04.07.20056788; doi:https://doi.org/10.1101/2020.04.07.20056788
- Henry C, Zaizafoun M, Stock E, Shamande S , Arroliga A et al. Impact
of angiotensin-converting enzyme inhibitors and statins on viral
pneumonia PROC (BAYL UNIV MED CENT) 2018;31(4):419–423
https://doi.org/10.1080/08998280.2018.1499293.
- David G. Harrison1, Tomasz J. Guzik, Heinrich Lob1, et al.
Hypertension. 2011 February ; 57(2): 132–140.
doi:10.1161/HYPERTENSIONAHA.110.163576.
- Solak Y, Afsar B, Nosratola D. Hypertension as an autoimmune and
inflammatory disease Hypertension
Research volume 39, pages567–573(2016).
- Marshall
R,
Webb S, Geoffrey
J. Bellingan , et al; Angiotensin converting enzyme
insertion/deletion polymorphism is associated with susceptibility and
outcome in acute respiratory distress syndrome. Am. J. Respir. Crit.
Care Med. 166, 646—650 (2002).
- Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of
statins, angiotensin II receptor blockers, and angiotensin-converting
enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis.
2012;55(11):1466–1473. doi:10.1093/cid/cis733.
- Kim J, Choi S-M, Lee J, Sik Park Y et al. Effect of Renin-Angiotensin
System Blockage in Patients with Acute Respiratory Distress Syndrome:
A Retrospective Case Control Study Korean J Crit Care Med 2017 May
32(2):154-163 https://doi.org/10.4266/kjccm.2016.00976
- Jerng J, Yu-Chiao Hsu, Huey-Dong Wu, et al. Role of the
renin-angiotensin system in ventilator-induced lung injury: an in vivo
study in a rat model. Thorax. 2007;62:527–535. doi:
10.1136/thx.2006.061945
- Zambelli
V, Bellani
G, Roberto
Borsa R et al. Angiotensin-(1-7) improves oxygenation, while reducing
cellular infiltrate and fibrosis in experimental Acute Respiratory
Distress Syndrome
Intensive Care
Medicine Experimental volume 3, Article number: 8 (2015).
- Deppe S. , Böger R. H. , Weiss J. , & Benndorf, R. A.
(2010). Telmisartan: A review of its pharmacodynamic and
pharmacokinetic properties. Expert Opinion on Drug Metabolism &
Toxicology, 6(7), 863–871. 10.1517/17425255.2010.494597
- McIntyre M, Caffe S. E. , Michalak R. A & Reid J. L.
(1997). Losartan, an orally active angiotensin (AT1) receptor
antagonist: A review of its efficacy and safety in essential
hypertension. Pharmacology & Therapeutics, 74(2), 181–194.